Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 251 of 6351
-
Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
Disease control Recruiting nowThis research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Phase 2 • Sponsor: Lakshmi Nayak, MD • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy shows promise for lung cancer brain metastases
Disease control CompletedThis study is a randomized, double-blind, placebo-controlled, multi-center clinical study. Target population is patients with stage IV non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of Camrelizumab + ca…
Phase 3 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for AML: gentler pill combo could replace harsh chemo
Disease control OngoingThis research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azac…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
A gentler path after surgery for HPV throat cancer?
Disease control OngoingThis is a non-randomized, open-label phase II clinical trial that studies the effect of reduced dose radiation therapy and chemotherapy after surgery in treating patients with human papillomavirus (HPV) caused throat cancer. Giving reduced dose radiation therapy and chemotherapy …
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Lung cancer Patients' own immune cells could shrink tumors in new trial
Disease control Recruiting nowThis is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a new drug offer hope for blood cancers when chemo fails?
Disease control CompletedTo assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy
Phase 2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New cocktail aims to make immunotherapy work for common colorectal cancer
Disease control CompletedImmunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, for proficient mismatch repair(pMMR)/microsatellite stable(MSS) CRC, the curative effect of PD-1 monoclonal…
Phase 2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a 'Paresthesia-Free' implant ease Post-Surgery leg pain?
Symptom relief OngoingSpinal cord stimulation (SCS) is a widely applied therapy to treat chronic neuropathic pain, and one of the most common indications is persisting radicular neuropathic pain following lumbar spine surgery. In traditional SCS therapies, the objective has been to replace the pain se…
Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can precision protons spare rectal cancer patients from harsh side effects?
Disease control Recruiting nowTo investigate a potential toxicity benefit of preoperative radiation therapy with protons compared to conventional photon beam radiation therapy in patients with locally advanced rectal cancer.
Sponsor: Alexander Valdman • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a pill shrink abnormal growths in PROS? new trial hopes to find out.
Disease control OngoingThis is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-rela…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug cocktail aims to stall Lymphoma's return
Disease control OngoingThis is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Engineered immune cells primed with decitabine show promise for tough lymphoma
Disease control OngoingThis is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma. A total of 19 to 33 patients are planned to be enrolled and receive decitabine-primed tandem CAR…
Phase 1/2 • Sponsor: Han weidong • Aim: Disease control
Last updated Jun 26, 2026 19:07 UTC
-
Mid-treatment PET scan may allow safer, lower radiation for throat cancer
Disease control OngoingThe purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-esca…
Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo pill shows promise for rare bone marrow cancer
Disease control OngoingA Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can virtual reality help quiet paranoia in schizophrenia?
Symptom relief CompletedThe study is a randomised, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment. A total of 256 patients will be allocated to either Cognitive Behavioural Virtual Reality Therapy plus treatment as usual, ver…
Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New radiation tile could change brain metastasis treatment
Disease control OngoingThis trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Phase 3 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a tiny dose of cannabis ease autism symptoms in children?
Symptom relief CompletedThis is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract \< 0.08% THC (FEN164) in children with Autism Spectrum Disorder.
Phase 1/2 • Sponsor: Fenix Innovation Group • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Could routine STI screening during pregnancy prevent preterm births?
Prevention CompletedThis study aims to evaluate different screening strategies to decrease the burden of Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV) among pregnant women, and reduce adverse birth outcomes. In turn it aims to evaluate the cost per pregnant wo…
Sponsor: Foundation for Professional Development (Pty) Ltd • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
Triple-Drug attack aims to outsmart mantle cell lymphoma
Disease control OngoingThis phase II trial studies the effects of acalabrutinib, umbralisib, and ublituximab in treating previously untreated mantle cell lymphoma. Acalabrutinib and umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Ublituximab is a m…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Diabetes drugs may reverse fatty liver damage in new trial
Disease control CompletedThe aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the antihyperglycemic drugs semaglutide and empagliflozin or empagliflo…
Phase 4 • Sponsor: German Diabetes Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC